Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers

被引:31
作者
Findlow, Jamie [1 ,2 ]
Bai, Xilian [1 ,2 ]
Findlow, Helen [1 ,2 ]
Newton, Emma [1 ,2 ]
Kaczmarski, Ed [1 ,2 ]
Miller, Elizabeth [3 ]
Borrow, Ray [1 ,2 ,4 ]
机构
[1] Publ Hlth England, Publ Hlth Lab, Manchester M13 9WZ, Lancs, England
[2] Manchester Royal Infirm, Manchester Med Microbiol Partnership, Manchester M13 9WZ, Lancs, England
[3] Publ Hlth England, Immunisat Dept, Hlth Protect Serv, London NW9 5EQ, England
[4] Univ Manchester, Inflammat Sci Res Grp, Sch Translat Med, Manchester M13 9PL, Lancs, England
关键词
Meningococcal; Vaccine; 4CMenB; ACWY-CRM; Laboratory workers; NEISSERIA-MENINGITIDIS SEROGROUP; IMMUNOLOGICAL HYPORESPONSIVENESS; POLYSACCHARIDE VACCINATION; GLYCOCONJUGATE VACCINE; UNITED-KINGDOM; HUMAN IMMUNITY; GROUP C; ANTIBODIES; ADULTS; STANDARDIZATION;
D O I
10.1016/j.vaccine.2015.05.027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Safety precautions for laboratory staff working with meningococci should primarily rely on laboratory procedures preventing exposure to aerosols containing viable meningococci. Despite this, vaccination is a key component of protection in the occupational setting. In the UK in 2009, there were no licensed vaccines for meningococcal capsular group B or conjugate vaccines for capsular groups A, C, W and Y. We therefore undertook a Phase II trial in laboratory workers to investigate the safety and immunogenicity of a four component group B vaccine (4CMenB) and a quadrivalent group A, C,W and Y conjugate vaccine (ACWY-CRM). Enrolment was open to staff aged 18-65 years at the Public Health Laboratory, Manchester who may have had a potential occupational exposure risk to meningococci. 4CMenB was administered at 0,2 and 6 months in the non-dominant arm and ACWY-CRM concomitantly at 0 months in the dominant arm. Pre- and post-vaccination blood samples were taken and analysed by the serum bactericidal antibody (SBA) assay against A, C, W and Y strains and a panel of seven diverse group B strains. Diary cards were used to record any local and systemic reactions following each vaccination. In total, 38 staff were enrolled and received initial vaccinations with 31 completing the trial per protocol. Both vaccines were proven safe, with local reactogenicity being more commonly reported following 4CMenB than ACWY-CRM. High proportions of subjects had putative protective SBA titres pre-vaccination, with 61-84 and 61-87% protected against A, C, W and Y strains and diverse MenB strains, respectively. Post-vaccination, SBA titres increased with 95-100 and 90-100% of subjects with protective SBA titres against A, C, W and Y strains and diverse MenB strains, respectively. These data suggest that 4CMenB and ACWY-CRM are safe when administered concomitantly and have the potential to enhance protection for laboratory workers. Crown Copyright (C) 2015 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:3322 / 3330
页数:9
相关论文
共 40 条
  • [1] An epidemiological review of changes in meningococcal biology during the last 100 years
    Abio, Anne
    Neal, Keith R.
    Beck, Charles R.
    [J]. PATHOGENS AND GLOBAL HEALTH, 2013, 107 (07) : 373 - 380
  • [2] Immunogenicity and Safety of Concomitant Administration of a Combined Hepatitis A/ B Vaccine and a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults
    Alberer, Martin
    Burchard, Gerd
    Jelinek, Tomas
    Reisinger, Emil C.
    Meyer, Seetha
    Forleo-Neto, Eduardo
    Dagnew, Alemnew F.
    Arora, Ashwani Kumar
    [J]. JOURNAL OF TRAVEL MEDICINE, 2015, 22 (02) : 105 - 114
  • [3] Safety and Immunogenicity of Typhoid Fever and Yellow Fever Vaccines When Administered Concomitantly With Quadrivalent Meningococcal ACWY Glycoconjugate Vaccine in Healthy Adults
    Alberer, Martin
    Burchard, Gerd
    Jelinek, Tomas
    Reisinger, Emil
    Beran, Jiri
    Hlavata, Lucie Cerna
    Forleo-Neto, Eduardo
    Dagnew, Alemnew F.
    Arora, Ashwani K.
    [J]. JOURNAL OF TRAVEL MEDICINE, 2015, 22 (01) : 48 - 56
  • [4] Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    Andrews, N
    Borrow, R
    Miller, E
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (05) : 780 - 786
  • [5] [Anonymous], IMM INF DIS GREEN BO
  • [6] Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
    Bai, Xilian
    Findlow, Jamie
    Borrow, Ray
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (07) : 969 - 985
  • [7] Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine
    Borrow, R
    Aaberge, IS
    Santos, GF
    Eudey, TL
    Oster, P
    Glennie, A
    Findlow, J
    Hoiby, EA
    Rosenqvist, E
    Balmer, P
    Martin, D
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) : 970 - 976
  • [8] Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls
    Borrow, R
    Southern, J
    Andrews, N
    Peake, N
    Rahim, R
    Acuna, M
    Martin, S
    Miller, E
    Kaczmarski, E
    [J]. VACCINE, 2001, 19 (23-24) : 3043 - 3050
  • [9] Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection
    Borrow, R
    Andrews, N
    Goldblatt, D
    Miller, E
    [J]. INFECTION AND IMMUNITY, 2001, 69 (03) : 1568 - 1573
  • [10] Safe laboratory handling of Neisseria meningitidis
    Borrow, Ray
    Findlow, Jamie
    Gray, Steve
    Taylor, Stephen
    Kaczmarski, Ed
    [J]. JOURNAL OF INFECTION, 2014, 68 (04) : 305 - 312